Why the study?
Does the choice of oral ADP-receptor antagonist (clopidogrel, prasugrel, or ticagrelor) impact 1-year mortality or bleeding in patients with acute myocardial infarction complicated by cardiogenic shock?
Does the choice of oral ADP-receptor antagonist (clopidogrel, prasugrel, or ticagrelor) impact 1-year mortality or bleeding in patients with acute myocardial infarction complicated by cardiogenic shock?
In patients with AMI complicated by cardiogenic shock, the choice of P2Y12 inhibitor does not independently predict 1-year mortality, though ticagrelor may be associated with lower in-hospital bleeding risk compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
P2Y12 inhibitor choice does not predict mortality in AMI cardiogenic shock; leaves open whether ticagrelor reduces bleeding pending randomized data.
This pooled sub-analysis is the largest analysis on safety and efficacy of three oral ADP-receptor antagonists and shows that acute therapy with either clopidogrel, prasugrel or ticagrelor is no independent predictor of 1-year mortality. Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared to clopidogrel. This finding might be due to selection bias and should be interpreted with caution.
No takes yet. Share an insight, caveat, or question.
Orban et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: